|
시장보고서
상품코드
2039029
말초신경병증 치료 시장 : 적응별, 치료법별, 최종사용자별, 지역별Peripheral Neuropathy Treatment Market, By Indication, By Treatment, By End User, By Geography |
||||||
말초신경병증 치료 시장은 2026년에 20억 7,190만 달러로 추계되고 있으며, 2033년까지 25억 6,470만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 3.1%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 20억 7,190만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 3.10% | 2033년 시장 규모 예측 : | 25억 6,470만 달러 |
세계의 말초신경병증 치료제 시장은 신경계 치료제 시장에서 중요한 부분을 차지하고 있으며, 말초신경계 장애로 인해 발생하는 일반적인 질환의 치료를 포함하고 있습니다. 이 질환은 통증, 무감각, 저림, 따끔거림, 근력 약화 등의 증상을 특징으로 하며, 환자의 삶의 질에 큰 영향을 미친다. 이 질환은 당뇨병, 화학요법에 의한 신경독성, 자가면역반응, 감염, 유전적 요인 등 다양한 원인에 의해 발생합니다.
전 세계 당뇨병 유병률 증가, 고령 인구의 증가, 신경계 질환에 대한 인식이 높아지면서 이 시장은 괄목할 만한 성장세를 보이고 있습니다. 이러한 요인으로 인해 이 질환의 치료를 필요로 하는 환자 수가 증가하고 있습니다. 의료 기관과 말초신경병증 치료제 제조업체들은 증상을 관리할 뿐만 아니라 질병의 진행을 어느 정도 막을 수 있는 새로운 치료법 개발에 투자하고 있습니다.
시장 역학
세계의 말초신경병증 치료제 시장은 주로 당뇨병 유병률 증가에 의해 주도되고 있습니다. 당뇨병은 신경장애의 가장 흔한 원인이며, 당뇨병 환자의 거의 50%가 신경장애를 경험하므로 지속적인 치료가 필요한 대규모 환자층을 형성하고 있습니다. 또한 암 환자 수가 증가함에 따라 생존율 향상으로 치료 부작용에 대한 대처가 중요해지면서 CIPN(화학요법 유발성 말초신경병증) 환자가 급증하고 있습니다. 고령 인구의 증가도 시장 성장을 촉진하는 중요한 요인 중 하나입니다.
그러나 말초신경병증의 이질성과 관련된 몇 가지 문제가 존재합니다. 이 때문에 이 질환의 진단과 치료는 상당히 어려운 질환입니다. 또한 혁신적인 의약품, 특히 진통제에 대한 규제 과정과 고품질 치료제의 높은 비용으로 인해 특히 개발도상국에서는 혁신적인 의약품의 광범위한 사용을 방해하고 있습니다. 또한 신뢰할 수 있는 바이오마커의 부족은 신약 개발 및 시험 속도를 저하시키고 있습니다. 그럼에도 불구하고 질환 조절약과 원격 환자 모니터링 및 원격의료를 포함한 디지털 헬스 기술 개발에는 미래가 있다고 봅니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 매출 창출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계의 말초신경병증 치료제 시장의 주요 기업 개요을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 세계의 말초신경병증 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 말초신경병증 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 쉽게 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 말초신경병증 치료 시장 : 적응별, 2021-2033년
제5장 세계의 말초신경병증 치료 시장 : 치료법별, 2021-2033년
제6장 세계의 말초신경병증 치료 시장 : 최종사용자별, 2021-2033년
제7장 세계의 말초신경병증 치료 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 애널리스트의 추천
제10장 참고 문헌 및 조사 방법
KSA 26.06.02Peripheral Neuropathy Treatment Market is estimated to be valued at USD 2,071.9 Mn in 2026 and is expected to reach USD 2,564.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,071.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.10% | 2033 Value Projection: | USD 2,564.7 Mn |
Global peripheral neuropathy treatment market represents an important part of the neurological treatments market which includes treatment of a common ailment that develops due to impairment of the peripheral nervous system. The condition is characterized by symptoms like pain, numbness, tingling, and muscle weakness which have a huge effect on the quality of patients' lives. The condition results from different causes such as diabetes mellitus, neurotoxicity, resulting from chemotherapy, auto-immune responses, infection, and genetics, among others
The market is experiencing substantial growth owing to increasing prevalence of diabetes around the globe, increased geriatric population, and high awareness of neuropathy diseases. These factors mean that there is increased number of patients requiring treatment for the condition. Healthcare organizations, as well as manufacturers of medications used to treat peripheral neuropathy, are investing in development of new therapies which not only manage the symptoms, but also help reverse some aspects of the disease.
Market Dynamics
The global peripheral neuropathy treatment market is mainly fueled by the increase in the incidence of Diabetes Mellitus, which is the most common cause of neuropathy and results in almost 50% of people with diabetes experiencing nerve damage, thus forming a large patient population that needs constant therapy. Moreover, the rise in cancer cases has led to an explosion in CIPN cases, owing to the higher survival rate resulting in an increased emphasis on coping with adverse effects of treatment. The increase in the geriatric population base acts as another important driver of the market's growth.
Nevertheless, there exist some difficulties associated with the heterogeneity of peripheral neuropathy. It makes diagnosing the condition and treating it rather problematic. Besides, the regulatory process for innovative drugs, especially pain killers, and the expensive nature of high-quality treatments reduce their availability on a wider scale, specifically in developing countries. Moreover, the lack of reliable biomarkers reduces the speed of developing and testing new medications. Nonetheless, prospects can be found in the creation of disease-modifying agents and digital health technologies, including remote patient monitoring and telemedicine.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global peripheral neuropathy treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Novartis AG, Johnson & Johnson, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AstraZeneca PLC, Sanofi, and Merck & Co., Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market
Market Segmentation
- Indication Insights (Revenue, USD Mn, 2021 - 2033)
- Diabetic Peripheral Neuropathy
- Chemotherapy-induced Peripheral Neuropathy
- Idiopathic Peripheral Neuropathy
- Others
- Treatment Insights (Revenue, USD Mn, 2021 - 2033)
- Pharmacological Therapies
- Non-pharmacological Therapies
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Ambulatory Centers
- Others
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Eli Lilly and Company
- Novartis AG
- Johnson & Johnson
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Abbott Laboratories
- AstraZeneca PLC
- Sanofi
- Merck & Co., Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Peripheral Neuropathy Treatment Market, By Indication
- Global Peripheral Neuropathy Treatment Market, By Treatment
- Global Peripheral Neuropathy Treatment Market, By End User
- Global Peripheral Neuropathy Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Peripheral Neuropathy Treatment Market, By Indication, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Diabetic Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Chemotherapy-induced Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Idiopathic Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Non-pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Peripheral Neuropathy Treatment Market, By End User, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Ambulatory Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Peripheral Neuropathy Treatment Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
